How ChatGPT, Perplexity, and Gemini describe prescription drugs in 2026

Spend a week asking ChatGPT, Perplexity, and Gemini the same set of prescription drug questions and a pattern emerges quickly. Each engine has a personality. They draw from overlapping but distinct sources. They fail in different ways. And the brand teams that understand those differences are the ones running monitoring programs that actually catch things in time to act on them.

This piece is a field-level read on how the three major answer engines describe prescription drugs to patients, clinicians, payors, and policymakers in 2026 — written for marketers and medical affairs leads who need to brief a team on what to measure.

How an answer engine actually builds an answer

Before any of the personality differences make sense, it helps to be precise about what the three engines are doing under the hood.

All three are large language models. None of them store a database of drug facts the way a clinical reference like Lexicomp does. Instead, each one assembles an answer from some combination of three ingredients: parametric knowledge (what the model learned during pre-training), retrieval (what the model fetched from the web at query time), and tool use (specialized function calls — a search index, a citation generator, a grounding system).

The mix differs by engine. That mix is most of why their answers look the way they do.

ChatGPT: the hedger

ChatGPT — particularly with the search preview enabled — produces the most cautious answers of the three on prescription drug questions. Ask about a specific brand and you'll typically get a short summary of the approved indication, mechanism of action, and a soft recommendation to consult a healthcare provider before making any decisions.

That caution is deliberate. OpenAI has spent years tuning ChatGPT to decline or hedge on personalised medical advice, and it shows up cleanly in the output. The upside for brand teams is that ChatGPT is less likely than the other two to make a confident incorrect statement. The downside is that the hedging itself can create commercial issues. A heavily disclaimed paragraph about your brand reads to a patient as "there is something risky here."

The other pattern that comes up with ChatGPT is what we'd call evidence flattening. When asked to compare two drugs in a class, it often gives a structurally identical paragraph about each, which reads as neutral but actually erases real differences in efficacy or labeling. A brand with a stronger overall survival benefit will sometimes get described in the same shape as a competitor with a weaker dataset, because the model is matching a template rather than weighing evidence.

Perplexity: the citer

Perplexity is the engine that pharma teams usually find most interesting. Its answers are shorter than ChatGPT's, more confident, and almost always cited inline.

That citation pattern is the headline feature. For any factual claim, Perplexity attaches a numbered source — usually a journal article, a regulatory document, a society guideline, or a major news outlet. For pharma, that's a double-edged signal. On the upside, you can trace exactly where the engine got each claim, which means you can identify whose content is shaping the answer. On the downside, Perplexity tends to weight whatever sources happen to be most prominent in the public web for a given query. That can mean Wikipedia, a competitor's case studies page, an old press release, or an unfavourable news cycle from two years ago.

The other Perplexity pattern worth knowing is conversational drift across follow-up questions. Ask "what is the mechanism of Pluvicto" and the answer is tight. Ask "and what are the side effects" as a follow-up and the engine sometimes picks up adverse events from a different drug entirely that was mentioned in one of the source pages it pulled. Brand teams that only test single-shot questions miss this entire failure mode.

Gemini: the grounder

Gemini sits closest to the Google search infrastructure. With Google Search grounding enabled — which is on by default for most queries through the consumer surface — Gemini's answers reflect what the live Google index is surfacing for that query.

For prescription drugs, that has a strong upside and a strong downside.

The upside is freshness. A new label change, a new HEOR publication, a new payor decision will show up in Gemini answers faster than in the other two engines, because Google's index updates daily. The downside is that Gemini sometimes pulls heavily from low-quality pages that happen to rank well — patient forums, content farms, outdated condition pages. The answer reads grounded because it has citations, but the citations are inconsistent in quality.

Gemini also tends to compress more aggressively than the other two. Where ChatGPT gives you four paragraphs and Perplexity gives you two, Gemini often gives you one. Brand teams sometimes read that as Gemini being "cleaner." What it actually means is that more of your evidence base is being left out of the answer.

Where the engines overlap

Despite the differences in personality, the three engines pull from a meaningfully overlapping set of sources for prescription drug questions. The big ones, in roughly the order of how often they appear in citations across the prompt sets we've audited:

• Wikipedia, especially for mechanism of action and broad indication framing
• FDA, EMA, and MHRA regulatory pages, especially for indications, dosing, and safety
• NIH, NCI, and Medline patient-facing condition pages
• Society guidelines: NCCN, ASCO, ESMO, AHA, ADA, depending on the therapeutic area
• Major journals: NEJM, Lancet, JAMA, plus PubMed abstracts
• Manufacturer-owned sites, usually the unbranded condition pages rather than the branded product pages
• High-traffic news outlets and trade press
• A long tail of patient advocacy and health-system content

Knowing this list matters because it tells you where to act. If every engine is citing your three-year-old unbranded condition page when describing your therapeutic area, that page is doing a lot of work whether you've refreshed it lately or not. If every engine is citing a competitor's patient advocacy partnership when describing the class, your medical affairs team has a real intervention to plan.

The four failure modes brand teams should monitor

Across the three engines, four recurring failure modes account for most of the issues a global brand team will care about.

Indication drift

The engine describes the brand for an indication, line of therapy, or patient population outside the approved label. This is the most loaded failure mode in pharma because it triggers a compliance review and almost always belongs with medical affairs, not the commercial team. The right detection signal is verbatim — what exactly did the engine say, and is the framing aspirational ("being studied in"), exploratory ("some clinicians use it for"), or definitive ("is used to treat").

Competitor halo

The engine answers a class-level or condition-level question by naming one or two competitor brands and omitting yours, even when the evidence base supports inclusion. This shows up most in crowded oncology and immunology classes. A good monitoring program tracks not just whether you're mentioned, but where in the response you appear — first, second, or buried after a list of others.

Outdated evidence

The engine cites a clinical or economic claim that has since been superseded by newer data. Common version: the engine is still quoting an older overall survival figure when a more recent analysis with longer follow-up exists. Even more common: the engine is still describing your brand's safety profile based on the original label when subsequent updates have refined it.

Audience mismatch

The engine gives an HCP-shaped answer to a patient question, or vice versa. A patient asking "what should I expect on Pluvicto" and getting a paragraph about radiation precautions in the same clinical register a nuclear medicine physician would use is a real failure mode. So is a clinician asking about second-line metastatic breast cancer options and getting a patient-friendly framing that leaves out the trial-level nuance.

What brand teams should be measuring

A useful monitoring program tracks a few things at the prompt-response level, not just at the workspace level.

First, visibility — what percentage of runs of a given prompt mention your brand at all. Second, position — when you are mentioned, where in the response do you appear. Third, sentiment — how the answer characterizes your brand, ranging from positive to negative with a few intermediate tones. Fourth, accuracy — how each substantive claim about your brand maps to your approved claims library. Fifth, share of voice — among the brands the engine mentions for a given question, what proportion of mentions are yours versus your competitors. Sixth, source mix — what kind of sources is the engine citing, weighted by your owned domains, competitor domains, regulators, journals, societies, news, and other.

Brand teams that try to collapse all of this into a single "AI score" tend to lose signal. The six dimensions answer different operational questions and should each have their own owner.

The takeaway

ChatGPT hedges. Perplexity cites. Gemini grounds. They all draw from the same handful of source families, and they all fail in the same four ways. The brand teams that take AEO seriously this year will be the ones who treat the three engines as distinct surfaces worth monitoring on their own terms — and who build the operational rhythm to act on what they find, week after week.